Neuroblastoma Global Clinical Trials Review, H1, 2016

GlobalData's clinical trial report, "Neuroblastoma Global Clinical Trials Review, H1, 2016" provides an overview of Neuroblastoma clinical trials scenario. This report provides top line data relating to the clinical trials on Neuroblastoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Reasons to buy

• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Neuroblastoma to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Neuroblastoma to Oncology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Neuroblastoma Therapeutics Clinical Trials 27
Prominent Drugs 29
Latest Clinical Trials News on Neuroblastoma 30
Apr 19, 2016: Kolltan Pharmaceuticals Announces Presentation of Preclinical Data for an Anti-ALK Monoclonal Antibody-Drug Conjugate (ADC) in Neuroblastoma Models at the 2016 American Association for Cancer Research (AACR) Annual Meeting 30
Clinical Trial Profile Snapshots 31
Appendix 352
Abbreviations 352
Definitions 352
Research Methodology 353
Secondary Research 353
About GlobalData 354
Contact Us 354
Disclaimer 354
Source 355

List of Tables

Neuroblastoma Therapeutics, Global, Clinical Trials by Region, 2016* 6
Neuroblastoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Neuroblastoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Neuroblastoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Neuroblastoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Neuroblastoma Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Neuroblastoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Neuroblastoma Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Neuroblastoma to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Neuroblastoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Neuroblastoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Neuroblastoma to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Neuroblastoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Neuroblastoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Neuroblastoma Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Neuroblastoma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Neuroblastoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Neuroblastoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Neuroblastoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Neuroblastoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Neuroblastoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Neuroblastoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Neuroblastoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures

Neuroblastoma Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Neuroblastoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Neuroblastoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Neuroblastoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Neuroblastoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Neuroblastoma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Neuroblastoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
Neuroblastoma Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Neuroblastoma to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Neuroblastoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Neuroblastoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Neuroblastoma to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Neuroblastoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Neuroblastoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Neuroblastoma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Neuroblastoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Neuroblastoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Neuroblastoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Neuroblastoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Neuroblastoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Neuroblastoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Neuroblastoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Neuroblastoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 353